- Premium Stock Alerts
- Posts
- Pre-Market Buzz: Capitalize on Early Opportunities
Pre-Market Buzz: Capitalize on Early Opportunities
Noor Saba
April 08, 2024
Don’t want emails from us anymore? Click here to unsubscribe
Hello Part-time Trader…👋
Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:
Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.
Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.
Top Pre-Market Movers: Identify early winners poised for a strong market opening.
Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.
FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.
Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.
Sponsored
Titanium Shortage Threatens Industry Titan
A titan of the aerospace industry announced it would no longer purchase titanium from Russia, a key supplier. With a global shortage of the lightweight "wonder metal" already in play, aerospace-grade titanium has become particularly scarce.
Will investors find new opportunity amid this titanium crisis?
Happening Today
✓ 10:00 AM ET – CB Employment Trends Index (Mar)
✓ 11:00 AM ET – NY Fed 1-Year Consumer Inflation Expectations
✓ 11:30 AM ET – 3-Month Bill Auction
✓ 11:00 PM ET – 6-Month Bill Auction
PREMARKET SNAPSHOT 📈
Stock futures climb, with the NASDAQ 100 leading the charge, up over 1.28%.
S&P500$5204.34 ⬆️ 1.10% | Dow$38904.04 ⬆️ 0.79% | NASDAQ$18108.45 ⬆️ 1.28% |
SECTOR SNAPSHOT ✨
Strong investor sentiment towards communication companies propelled the Communication Services sector to the top, with a gain of 1.61%.
NAME | PRICE | %CHANGE |
|---|---|---|
Consumer Discretionary | 1,457.52 | +0.94% 🟢 |
Consumer Staples | 792.47 | +0.22% 🟢 |
Energy | 749.39 | +1.09% 🟢 |
Financials | 691.31 | +0.90% 🟢 |
Health Care | 1,671.01 | +0.91% 🟢 |
Industrials | 1,064.12 | +1.43% 🟢 |
Materials | 584.35 | +0.92% 🟢 |
Real Estate | 240.85 | +0.65% 🟢 |
Information Technology | 3,782.91 | +1.38% 🟢 |
Communication Services | 291.30 | +1.61% 🟢 |
Utilities | 331.02 | +0.35% 🟢 |
Sponsored
Top 5 "Portfolio Supercharging" Stocks - Free Report from Zacks Investment Research
Zacks has a proven track record for picking big winners. And now, our team of experts has hand-selected, from thousands of companies, the 5 stocks they predict they have outsized gain-potential NOW and in the coming year.
Recent recommendations have climbed as high as +288%. In fact, our newest report could point to even bigger gains. These picks will surprise you and current market conditions could make our new recommendations even more profitable. This special arrangement is good for a limited time only.
I urge you to act now!
Unusual Volume
📈 MediaCo Holding Inc (MDIA) jumped 177.14% to $3.88 on a whopping 118.01 million shares traded after after the company updated investors on the stake held by Standard General L.P. CEO Soohyung Kim.
📈 Investors went wild, sending Hub Cyber Security Ltd (HUBC) stock soaring 48.08% to $1.54 on a massive volume of 93.67 million shares after the company announced a successful $8 million financing acquisition via a straight debt arrangement.
📈 Abnormal activity shook SuperCom Ltd (SPCB), pushing it up 37.14% to $0.29 on a whopping 88.08 million shares traded.
📈 Candel Therapeutics Inc (CADL) stock recently closed 3.75% upper at $6.64 on substantial volume of 83.7 million shares. This unusual activity came after the company released new data from a trial of its experimental cancer treatment.
📈 22nd Century Group Inc (XXII) increase by 140.54% in a single trading session, with abnormally high trading volume of 72.21 million shares after the company announced a “significant” new contract manufacturing agreement.
Sponsored
NOW is the time to get in on this trillion-dollar megatrend
Now is the time to position yourself for the next round of explosive growth from what will soon be a trillion-dollar market. But don't chase yesterday's winners!
The AI hype is off the charts and some AI stocks have run so far that they are looking WAY overvalued. When they crash back down to earth, some investors could get hurt. I don't want that to happen to you! So I'm making our new special report on the best AI stocks to own now free for a limited time.
Get it here.
Premarket Movers
Antelope Enterprise Holdings Limited (AEHL) experiences a substantial 38.92% surge in pre-market trading after filing 6-K form with the SEC.
U Power Limited (UCAR) sees a significant 53.19% increase, reaching a pre-market price of $7.20 after announcing that its battery-swapping and sharing model for two-wheeled and light four-wheeled electric vehicles (EVs) is poised for a formal commercial rollout in Wuhu, Anhui Province, China.
Marathon Digital Holdings, Inc. (MARA) demonstrates a noteworthy 6.29% surge, with a pre-market price of $19.60. The company announced the appointment of Vicki Mealer-Burke to its board of directors, effective April 1, 2024.
Pre Market Gainers | Pre Market Change | Pre Market Volume |
|---|---|---|
SLNA | +65.34% | 11.32M |
LGVN | +65.00% | 2.39M |
BCAN | +26.21% | 2.24M |
AEHL | +38.92% | 2.09M |
UCAR | +53.19% | 1.85M |
MARA | +6.29% | 530.73K |
SMFL | +11.52% | 462.70K |
CLSK | +7.50% | 344.41K |
GLMD | +19.95% | 315.67K |
GRRR | +9.58% | 238.34K |
Sponsored
See What One Ticker... One Trade... EVERY WEEK... Can Do for YOU
New research proves that trading one ticker every week has had the ability to produce extraordinary gains...
Including a rare 2,614% in under 11 days.
See this groundbreaking new discovery for yourself.
Show me one ticker payouts.
Important FDA
Recently Announced
Vanda Pharmaceuticals (VNDA) secured FDA approval for an expanded use of Fanapt, allowing its use in treating manic or mixed episodes associated with bipolar I disorder in adults. This significant development enhances options for individuals battling this challenging mental health condition.
AbbVie's (ABBV) ELAHERE, initially granted accelerated approval, has now earned full FDA approval for certain patients with platinum-resistant ovarian cancer. This transition underscores the drug's efficacy and paves the way for improved treatment outcomes in this patient population.
Bristol-Myers Squibb Co.'s (BMY) Opdivo, in combination with cisplatin-based chemotherapy, has been approved as a frontline treatment option for adult patients with unresectable or metastatic urothelial carcinoma. This approval reflects the potential of this therapeutic approach to address a critical need in oncology care, offering new hope to those affected by this aggressive cancer subtype.
Upcoming Announcements
On April 23, 2024, ImmunityBio, Inc. (IBRX) anxiously awaits the FDA's decision on N-803 plus BCG for high-risk non-muscle-invasive bladder cancer, hoping for a treatment breakthrough.
April 28, 2024, marks a crucial moment for Aquestive Therapeutics Inc. (AQST) as they await the FDA's verdict on Libervant, offering potential relief for pediatric epilepsy if approved.
As April 30, 2024, approaches, Neurocrine Biosciences Inc. (NBIX) stands at the brink of progress, anticipating FDA approval for INGREZZA oral granules, potentially revolutionizing tardive dyskinesia treatment.
Happy investing,
Maeve Grace
Editor In Cheif
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply